Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$16.3M
5 rounds on record
Latest round
$338k
Venture round · Feb 2025 · 19 mo ago
Team
18
US Form 5500 (plan participants) · Dec 2025 · -14% in a year
The money's age
Due for its next round
19 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 13, 2025
Raised a round Venture round $338k · SEC Form D
Aug 29, 2024
Raised a round Venture round $3.1M · SEC Form D
Dec 14, 2023
Raised a round Convertible Note $332k · SEC Form D
Mar 8, 2023
Raised a round Convertible Note $1.8M · SEC Form D
Jun 2, 2022
Raised a round Venture round $10.7M · SEC Form D
2019
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Feb 2025 | $338k | — | SEC Form D |
| Venture round | Aug 2024 | $3.1M | — | SEC Form D |
| Convertible Note | Dec 2023 | $332k | — | SEC Form D |
| Convertible Note | Mar 2023 | $1.8M | — | SEC Form D |
| Venture round | Jun 2022 | $10.7M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Ordaos, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
David LongoExecutive Officer, DirectorSEC Form D
Similar startupsby what they do, their industry and backers
ConvergeAB™ designs and optimizes antibodies for selection, lead optimization, and de novo generation across IgG, VHH, scFv, and…
We sequence proteins. Glyphic Biotechnologies is decoding the human proteome through full coverage, de novo protein sequencing at single…
Monod Bio launched in 2022 as a spin-out from the Baker Lab. Since then, we have been using AI-powered de novo protein design to create RUO…
Anchored by our protein-engineering expertise and our proprietary single-domain antibody platform, we’ve developed a unique pipeline of…
Genialis is a precision oncology company helping the most promising molecules become life-saving medicines.
Seamless and life-saving stroke care with Synapse AI, Sevaro's virtual neurology services & advanced human-AI integration.
News
Exclusive: Quercus Biosolutions emerges from stealth to disrupt crop protection with designer mini proteins
Quercus Biosolutions is a startup using generative AI to create a new generation of crop protection products based on designer mini proteins.
Read more
Report
People
David Longo
Executive Officer, Director
Ulo Palm
Director
Benjamin Britt
Director
Scott Horner
Director
James Ramey
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
New York
United States
HQ
Join
50-200 est. staff
228 Park Ave S 60684,, New York, NY 10003, USA
Financials
Total raised
$16.3M
Latest round
Venture - Series Unknown
Funding rounds
5